1 – 32 of 32
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer
(
- Contribution to journal › Article
-
Mark
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes
(
- Contribution to journal › Article
- 2023
-
Mark
UROSCAN and UROSCANSEQ : a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice–from biobank to RNA-sequencing in real time
(
- Contribution to journal › Article
-
Mark
Urodrill - a novel MRI-guided endoscopic biopsy technique to sample and molecularly classify muscle-invasive bladder cancer without fractionating the specimen during transurethral resection
(
- Contribution to journal › Article
-
Mark
Tumor Biomarkers for Bacillus Calmette-Guérin Response : What We Get Is Not What We Want
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The Lund taxonomy for bladder cancer classification – from gene expression clustering to cancer cell molecular phenotypes, and back again
(
- Contribution to journal › Scientific review
- 2022
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter
-
Mark
Molecular pathology of the non-luminal Ba/Sq-like and Sc/NE-like classes of urothelial tumours : An integrated immunohistochemical analysis
(
- Contribution to journal › Article
-
Mark
The Lund Molecular Taxonomy Applied to Non-Muscle-Invasive Urothelial Carcinoma
(
- Contribution to journal › Article
-
Mark
Patient-Derived Bladder Cancer Organoid Models in Tumor Biology and Drug Testing : A Systematic Review
(
- Contribution to journal › Scientific review
-
Mark
Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review
(
- Contribution to journal › Scientific review
-
Mark
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
(
- Contribution to journal › Article
-
Mark
A comparison of rule-based and centroid single-sample multiclass predictors for transcriptomic classification
(
- Contribution to journal › Article
- 2021
-
Mark
When the Molecular Subtype Is Hidden Behind a Veil of Stroma
(
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer : A Step in the Right Direction but Still a Long Way To Go.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Molecular changes during progression from nonmuscle invasive to advanced urothelial carcinoma
(
- Contribution to journal › Article
-
Mark
Recurring urothelial carcinomas show genomic rearrangements incompatible with a direct relationship
(
- Contribution to journal › Article
-
Mark
Re : A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http://doi.org/10.1016/j.eururo.2020.06.048
(
- Contribution to journal › Letter
- 2019
-
Mark
Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival
(
- Contribution to journal › Article
-
Mark
Molecular pathology of the luminal class of urothelial tumors
(
- Contribution to journal › Article
- 2018
-
Mark
A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort
(
- Contribution to journal › Article
-
Mark
Discordant molecular subtype classification in the basal-squamous subtype of bladder tumors and matched lymph-node metastases
(
- Contribution to journal › Article
-
Mark
Molecular subtype classification of urothelial carcinoma in Lynch syndrome
(
- Contribution to journal › Article
- 2017
-
Mark
HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
(
- Contribution to journal › Article
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Molecular classification of urothelial carcinoma : global mRNA classification versus tumour-cell phenotype classification
(
- Contribution to journal › Article
- 2015
-
Mark
Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.
(
- Contribution to journal › Article
-
Mark
Reply from Authors re: Bas W.G. van Rhijn, Mark A. Behrendt, Kees Hendricksen, Theo H. van der Kwast. Toward Optimal Prediction of Prognosis in T1 Urothelial Carcinoma of the Bladder. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.03.030.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
(
- Contribution to journal › Article
-
Mark
On Molecular Classification of Bladder Cancer: Out of One, Many.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Biological determinants of bladder cancer gene expression subtypes.
(
- Contribution to journal › Article
- 2013
-
Mark
Toward a Molecular Pathologic Classification of Urothelial Carcinoma.
(
- Contribution to journal › Article